CD274 and triple-negative breast carcinoma: A study by Schmid and Loi, published in the Lancet Oncol, showed that atezolizumab plus nab-paclitaxel has a significant clinical effect on PD-L1 positive triple-negative breast cancer after a Phase 3 clinical trial.